Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,749.05
(
0.74%
)
US TECH 100
24,124.80
(
0.46%
)
Dow Jones
47,378.05
(
0.92%
)
Brent Oil
99.02
(
0.73%
)
Bitcoin
73,777.06
(
-1.43%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: 10nisman post# 111373

Thursday, 12/23/2010 12:11:56 PM

Thursday, December 23, 2010 12:11:56 PM

Post# of 257251

This response supports Teva's belief that even slight changes to a glatiramoid like Copaxone® can significantly and unpredictably influence the efficacy, toxicity and immunogenicity profile of the compound.



Teva is on par with ARNA CEO in spinning nonsense now.

If they turely believed so, why would they submit sNDA in the first place?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today